IP Insights
KIPO Accelerates Biotech, AI, and Robotics Patents: A Portfolio Timing Playbook
•
9 min read
•Views 264
Updated:
//
The standard patent prosecution timeline at KIPO creates a strategic gap. In 2024, the average pendency to a first office action across all technologies was 16.1 months. For a Korean company racing to secure freedom-to-operate before a product launch, close a funding round, or file a PCT application, a 16-month wait forces a choice: delay the commercial milestone or proceed without a registered right. The bottleneck is most acute in fast-moving fields where the technology cycle is shorter than the prosecution cycle.
On February 19, 2025, KIPO expanded its prioritized examination program to cover biotech, artificial intelligence, and advanced robotics. These three fields join semiconductors (added November 2022), displays (November 2023), and secondary batteries (February 2024). The four designated national strategic technology sectors are now all eligible. KIPO also widened the scope for secondary batteries to include performance testing, battery management systems, and recycling, and extended green-technology prioritization to hydrogen, small modular reactors, and renewable energy production.
The operational target is a first office action within two months for qualifying applications. The precedent is concrete: for semiconductors and displays, the average prioritized pendency was 1.6 months as of end-December 2024, against a standard pendency of 13.7 months for those fields. KIPO projects that the overall average pendency across all technologies will drop from 16.1 months in 2024 to 15.1 months in 2025.
Eligibility requires that the application carry a relevant CPC code as its primary classification and that the applicant be a company producing or preparing to produce in Korea, a national R&D project outcome, or a filing from a specialized university. KIPO also relaxed the evidentiary burden: a technology transfer agreement now suffices to prove implementation readiness, replacing the previous requirement for a business registration certificate. The self-conducted prior art search requirement was deleted entirely.
Three procedural changes reinforce the speed advantage for global filers. First, KIPO will prioritize the domestic application that serves as the priority basis for a PCT filing, smoothing the path to subsequent foreign filings. Second, the PPH processing deadline shrinks from four months to three months, aligning with parallel improvements in the US and Japan. Third, divisional applications will now be examined in the order of their own examination request date, not the parent’s, matching USPTO and JPO practice. The deadline to request re-examination after a final rejection extends from one month to six months starting April 2025, giving applicants more time to amend claims without immediately appealing to the IP Trial and Appeal Board.
KIPO is staffing up to meet the demand: 67 examiners were added for semiconductors in 2023–2024, 38 for secondary batteries in mid-2024, and 60 new examiners from private-sector experts will be hired in 2025 for biotech (35), AI (9), and robotics (16).
The two-month window changes the filing-timing equation. A Korean AI startup planning a Series B round can file a KIPO application, request prioritized examination, and reasonably expect a granted patent (or at least a clear allowance signal) before the data room opens. The same logic applies to a biotech company negotiating a licensing deal or a robotics firm preparing a product launch. The key action is to align the KIPO filing date with the commercial calendar, not merely with the 12-month Paris Convention deadline.
For Korean applicants who file domestically first and then abroad, the new rule prioritizing the PCT-basis application means the domestic case will move faster, generating a search report and written opinion that can be used in subsequent national-phase entries. Practitioners should build this into their drafting workflow: file the Korean application with claims that are already structured for international use, because the first office action will arrive quickly and the window for voluntary amendment is compressed.
For foreign filers using the PPH, the shortened three-month KIPO deadline means a PPH request must be prepared in parallel with the first allowance in the home office, not after. IP managers should pre-identify which US or JP cases are likely to serve as PPH bases and align claim correspondence early. The change to divisional examination order also means a divisional filed today will not jump the queue by riding its parent’s earlier request date; it will be examined in its own turn. If a competitor is likely to file a divisional to pursue a narrower scope, the delay may create a window to challenge validity or design around before the divisional is examined.
Korean companies that are both patentees and potential challengers, as many large conglomerates are, should hedge. The accelerated timeline benefits a patentee who needs a registered right quickly to assert against a competitor or to strengthen a licensing position. But the same acceleration means a competitor’s application in your field will also be examined faster, compressing the time available to file a third-party observation or prepare an invalidation strategy. Monitor KIPO’s published prioritized-examination filings in your technology CPC codes monthly, not quarterly.
One final drafting discipline: because the self-conducted prior art search is no longer required, the examiner will rely more heavily on the office’s own search. Draft the background section and the claims to explicitly distinguish the invention from the closest known art you are aware of. Do not assume the examiner will find the same distinctions without guidance. A well-drafted specification that frames the problem and the solution clearly reduces the risk of a surprise rejection in the accelerated timeline.